close acquisit issu revis pro-forma model note
detail refin model sale ep estim intact
ep forecast ultim prove conserv like stem higher oper
margin current forecast estim may chang post manag issu
guidanc combin entiti
detail refin model
oper margin new model reflect higher oper margin larg due lower
sg forecast oper margin vs previous
vs previous vs previous forecast
sg vs respect
last publish model vs
respect last publish model gross target intact
rais
interest expens new model fulli reflect interest expens pay
four sourc debt debt includ legaci
debt weight averag coupon rate bond issu financ
acquisit weight averag coupon rate accru interest
expens sinc reflect non-gaap
close acquisit earlier month close acquisit took
term loan term loan credit agreement put place last juli rate
disclos assum inherit legaci debt weight averag
coupon rate total debt balanc therefor plu non-cash mark-
to-market fair valu adjust legaci debt per purchas account rule
plan pay debt end plan
de-lever goal pay bond issu
financ acquisit estim interest expens
two-class method calcul ep adjust use two-class method
calcul ep proport share particip approxim
reflect subtract net incom prior divid averag
pleas see page report import disclosur
invest case larg key dividend yield valuat
fact manag plenti time find addit sourc growth
support year addit sourc growth key sinc abbv agn sale
ep appear like peak erod due humira patent
expir promis new product line-up pipelin might
unappreci could support long-term sum total return/p
group averag basi argu purchas share
rinvoq roll-out ra
skyrizi /eu uptak psoriasi
new indic competit
landscap venclexta/imbruvica
humira sale trend eu
recoveri aesthet busi
humira sale
humira biosimilar eros less
especi oncolog immunolog
 bolster long-term visibl
humira erod quickli
oncolog immunolog product
global biopharmaceut compani product use treat rheumatoid
arthriti psoriasi crohn ulcer coliti hcv hematolog tumor among other
humira ra crohn domin product repres total sale
profit also pipelin compound indic phase
ii phase develop may acquir allergan brought strong
posit aesthet ophtham women
compani data cowen compani
revenu good sold good sold profit profit profit margin profit margin profit profit margin royalti profit gross profit gross profit margin profit gross profit gross profit margin revenu revenu oper ens incom revenu foreign exchang gain loss interest ens incom ens net interest ens -inherit ens interest incom revenu tax rate incom oper method revenu dilut chang share per share financ cash share combin compani assum share outstand new debt assum remaind cash cowen
compani data cowen compani
stand-alone guidanc approx oper growth revenu good sold good sold profit profit profit margin profit margin guidanc ramp base bmy/celg merger assumptionsgross profit gross profit margin royalti pay royalti global humira sale end end end end profit profit roch assum sg atot gross profit ou sale roch assum gross profit margin profit share profit total gross profit gross profit margin stand-alone guidanc approch assum guidanc ramp base bmy/celg merger assumptionssg revenu stand-alone guidanc approx assum guidanc ramp base bmy/celg merger assumptionsr revenu stand-alone guidanc oper ens incom revenu stand-alone guidanc approach guidanc foreign exchang gain loss interest ens stand-alone guidanc approx incom ens net interest ens -inherit exist model assum paydown exist debt transact paid offinterest ens interest int debt reduc subsequ pre-tax incom revenu tax rate stand-alone guidanc approx incom oper method revenu dilut stand-alone guidanc chang ep quarter two-class method calcul ep share issu share purchas share per share financ cash share combin compani assum share outstand new debt assum remaind cash cowen
compani data cowen compani
ww foreign lc ex chang chang foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww guidanc us growth ou ip expect hold settlement launch start humira biosimilar launch eu foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach chang chang guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close guidanc growth acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid- guidanc flat steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid guidanc flat line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagis- guidanc flat foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launchedandrogel testosteron gel hypergonad market declin gener pressurekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
guidanc hcv combin glecaprevir pi pibrentasvir hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex approv cll delet r/r cll rituxanvenclexta venetoclax select inhibitor cllorilissa- oral gnrh antagonist partial estrogen suppress guidanc endometriosi approv uterin fibrosi file partnership neurocrin eign lc ex similar lupron zoladexorilissa hold ww right elagolix gnrh antagonistsskyrizi- rizankizumab guidanc approv psoriasi ph crohn uc ph ii eign lc ex month bi bi receiv mileston royaltiesduodopa- guidanc infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson prodrug data guidanc ra roll-out underway ph atop dermat ph ii axspa gca eign lc ex jak inhibitor competit profil ra crohn uc ad combo btk cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl myeloma r/r mm w/poma dexveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase inhibitor refractori anti-tnf/steroid phase ii vs humira pivot trial util sq formpipelin full navitoclax sale reflect foreign lc ex foreign lc ex world-wide cowen
compani data cowen compani
 bimatoprost glaucoma combin lumigan timolol lubric eye drop dexamethason treat infecti uveiti cyclosporin chronic dri eye patent protect gener yet total ophthalm franchis remain key franchis new product launch key outlook competit dynam moder assum covid pressur spastic migrain incontin resili covid pandem total botox franchis nervou namenda memantin moderate/sever alzheim diseas cariprazin atyp milnacipran serotoninnorepinephrin reuptak inhibitor escitalopram ssri antidepress major depressive/gener anxieti ssri partial agonist major depress atyp schizophrenia gx approv assum central nervou strong franchis estimate guanyl cyclas agonist ibs-c chronic idiopath constip mesalamin moder activ uc rectal bleeding/frequ bowel short-term treatment od dueoden mild/moder ulcer proctitit eluxadolin acquir furiex linaclotid guanyl cyclase-c agonist ibs-c chronic constip viokac pylera rectiv aquadek scandishak salofalk ultresatot strong gi franchis addit est/aptali furiex cowen
compani data cowen compani
lo loestrin lo loestrin fe ethinyl estradiol norethindron ferrou levonorgestrel-releas mg intrauterin systemestrac estradiol menopaus sx gener introduc late decemb norethindron acet ethinyl estradiol ferrou fumar capsulesoth women atelvia crinon diafert levosert generess fe metronidazol fibristaltot women market leader hypertens combin product specif beta blocker via jnjtotal silodosin bph reliev urinari symptom associ enlarg prostat inject broad-spectrum cephalosporin cap novel cephalosporin/beta lact us rights/azn rowoth infecti establish sale forc pipelin product skin rejuven vitamin retinol tea tree oil salicyl acid bimatoprost eyelash growth deoxychol acid destroy fat cell decreas fat hang chin aczon topic antimicrobi formul acn tazorac tazaroten topic retinoid cream gel foam tx psoriasi acn sun damag devic use cryolipolysi proceduresoth medic dermatology/skin dermatolog estimate salin silicon other devel assum covid pressur juvederm line success assum covd pressur revenuelifecell/acellular dermal soft tissu substitut deriv donat human skin tx burn woundsarmour thyroid hormon treat underact cowen
compani data cowen compani
pipelin product ubrogep oral cgrp acut treatment migrain roll-out underway ghrelin/ghsr agonist diabet gastroparesi ci constip anorexia nervosa file mucin secret analog dri eye complimentari lifitegrast/restasi nmda receptor antagonist treatment-resist depress longer-dur anti-vegf potenti dose dme safeti concernstot acquisit close cowen
compani data cowen compani estim
record sale ou sale approv hematolog ra pa crohn psoriasi jia uc uveiti hs biosimilar expect jak inhibitor competit profil ra crohn uc ad btk combo rizankizumab month bi bi receiv mileston venetoclax select inhibitor all-or hep regimen genotyp ifn-nav hcv patient elagolix endometriosi launch uterin fibroid file lead market despit gener line extens prevent rsv right foreign testosteron replac gener form launch franchisenew duopa emplic acquir cash/stock estimate close botox vraylar linzess versu industri averag cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success recent
launch pipelin product success integr
